Crinetics Pharmaceuticals ($CRNX) has generated 3 mentions from 3 distinct FinTwit voices over the past 12 months, with discussion beginning on September 25, 2025. The biotech-focused mentions span from the initial mention by @jonerlichman through most recent commentary by @kaizen_investor on March 17, 2026. Key coverage included FDA approval news for the company's acromegaly drug and financial metrics discussion, with the company operating at a market capitalization of $3.9 billion and demonstrating a five-year revenue compound annual growth rate of 164.7%.